Speakers / Chairs icon
Speakers / Chairs
Exhibition icon
Exhibition
Abstracts icon
Abstracts
Information icon
Information
Live icon
Live
Awards icon
Awards
Information icon
Information
Information icon
Information
Information icon
Information
Archive icon
Archive
Saturday 03.11.2007
Scientific Session
Satellite Symposium
Main Program
Workshop
calendar export icon
Export calendar
Myocardial Infarction Mortality Risk after Treatment for HL: a Collaborative British Cohort Study
Risk Factors for Cardiovascular Disease; Dutch Results
Clinical Applications of Modelled Second Cancer Risk Among HL Survivors
Breast Tumors Induced by High-dose Radiation Display Similar Genetic Profiles
Screening for Lung Cancer in Patients at High Risk of this Second Cancer after Treatment for HL
Breast Cancer Screening with MRI in Female HL Survivors
Cytokine Gene Expression and T-Cell Transcription Factor Profile of the T-Cells of the Nodular Lymphocyte Predominance Type of HL
Double-Positive CD4+CD8+ T-Cell Populations in Nodular Lymphocyte Predominant HL: Further Characterization and Relationship to Other Entities
CD4/CD8-double Positive T-Cells in Nodular Lymphocyte Predominance HL
Regulatory T-Cells in Classical HL
Biologic Prognostic Markers in cHL: Evaluation of Characteristics of RS Cells as well as the Tumor Infiltrating Lymphocytes
dentification and Purification of Hodgkin Cells from Lymph Nodes Involved by Classical HL by Flow Cytometry and Flow Cytometric Cell Sorting
Allogeneic Hematopoietic Cell Transplantation for HL
Allogeneic Stem Cell Transplantation (Allo-SCT) in HL: The European Point of View
Improved Outcome Following Reduced Intensity Allogeneic Transplantation in HL Relapsing Post-Autologous Transplantation
Allogeneic/Syngeneic/Autologous Transplantation – a Comparison
Current Protocols and Concepts in the USA
Strategy of the EuroNet-PHL-C1 Protocol for the Treatment of Classical HL in Children and Adolescents
First International Inter-Group Study for Lymphocyte Predominant HL in Children and Adolescents
Current Children’s Oncology Group (COG) Protocol for LPHL
The new trial generation of the German Hodgkin Study Group (GHSG)
The H10 EORTC/GELA Randomized Intergroup Trial on Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supradiaphragmatic Stage I/II HL
Response-Adapted Therapy Using FDG-PET Scanning after Initial ABVD: The UK NCRI, Italian and Nordic Trial in Advanced HL
Identification of Relevant and Practical Questions for an Transatlantic Intergroup Designs
Development of ABVD as Standard Treatment for HL
Organisation Central On-line PET Review
RNA Expression Analyses of whole Tissue Sections
The Role of Inflammatory Bystander Cells in HL
Gene Expression Profiling in HL: the RS Cells or the Microenvironment?
Elevated levels of HLA-B associated transcript 3 (BAT3) in sera from Hodgkin Lymphoma patients
The EBV-encoded EBNA1 in HL Cells Mediates Upregulation of the Chemokine CCL20 and the Migration of Regulatory T-Cells
Aberrant Notch1 Activity Contributes to Plasticity of HRS Cells
Sunday 04.11.2007
Scientific Session
Satellite Symposium
Main Program
Workshop
calendar export icon
Export calendar
Molecular Immunogenetics of B Cells and HRS Cells
Translocations in HRS Cells
The Plasticity of HRS Cells
The Role of microRNA for Regulation of PRDM1/Blimp-1in HRS Cells
BIC and other miRNAs in HL
HL: Evidence for a Cancer Stem Cell and Therapeutic Implications
Induction of Hodgkin-like Phenotype by Epigenetic Reprogramming of B Cells
3D Nuclear Organization of Telomeres in HRS Cells
KLHDC8B: a Candidate HL Susceptibility Gene
Analysis of Genetic Predisposition to Hematotoxicity in HL
Serum Profiling of Cytokines
Targeted Treatment Approaches in HL
How to Select Novel Small Molecules for Early Clinical Testing
Proteomics Analysis of HL: Identification of New Players Involved in the Cross Talk between HRS Cells and Infiltrating Lymphocytes
Galectin 1 Mediates Tumor Escape in HL
Session details
12:15–13:45
Satellite Symposium
Prophylaxis and Treatment of Side Effects of Chemotherapy: Casuistic Forum
Room: Großer Saal
Anaemia in Patients with Hodgkin Lymphoma
Neutropenia in Patients with Aggressive NHL
Mucositis in Patients with Relapsed Lymphoma
Session details
14:00–15:30
Satellite Symposium
Innovative Strategies in the Therapy of Hematological Malignancies
Room: Großer Saal
Velcade – Lead Compound in Multiple Myeloma?
Future Directions in the Treatment of MDS
Velcade – Innovative Therapy Options in NHL
Efficient Hb Management in Lymphoma: Results of the HD15 Protocol
Pathogenesis of B-Cell Lymphomas and Identification of Molecules Suitable for Targeted Therapy
Review of Immuno-Chemotherapy in Aggressive and Follicular Lymphoma
State of the Art Therapy Non Hodgkin Lymphoma in the USA
Role of Immuno-Chemotherapy in HL
New treatment approaches in Aggressive Lymphoma: Intensified Immuno-Chemotherapy - Anti-VEGF + Immuno-Chemotherapy
New Treatment Approaches in HL: Emergence of Anti-VEGF as a New Modality in HL
From the Absorbent Gland to the “Molecular Cure” of Hodgkin Lymphoma
Monday 05.11.2007
Scientific Session
Satellite Symposium
Main Program
Workshop
calendar export icon
Export calendar
Screening in High Risk Groups
Pulmonary and Cardiac Toxicity in HL Survivors
How to Preserve Fertility in HL Patients
Efficacy and Toxicity of Treatment of HL /Mature Data from a Single Centre
Causes of Death and Excess Mortality after HL: the EORTC-GELA Experience
Survival Patterns among HL Patients with a Family History of Lymphoma
Defining the Role of Radiation Therapy (RT)
Combined Modality Approaches
Results of the EORTC-GELA H9 Randomized Trials: the H9-F Trial (Comparing 3 Radiation Dose Levels) and H9-U Trial (Comparing 3 Chemotherapy Schemes) in Patients with Favorable or Unfavorable Early Stage HL
Stage I/II HL with Bulky Mediastinal Disease or other Risk Factors; The Stanford V Experience
Chemotherapy is Essential for Optimal Treatment of Limited Stage Nodular Lymphocyte Predominant HL
Hodgkin Lymphoma: Better Cure with or without Procarbazine?
Therapy of primary CNS-Lymphomas: What’s new?
Molecular Predictors and Prognostic Markers in Brain Tumours.
What can we learn from Randomized Trials with Patients with Anaplastic Gliomas?
Investing in the Future of Cancer Patients
Summary and Closing Remarks
GHSG Trials in Relapsed HL
The Role of Gemcitabine in the Treatment of Primary and Relapsed Disease
Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone (IGEV) and Fixed Dose of Lenograstim: an Effective Mobilization Regimen in Pretreated HL Patients
A Phase II Study of MGCD0103, a Novel Oral Isotype-Selective Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory HL
Promising Results for Patients with Relapsed or Refractory HL Treated with the Oral mTOR Inhibitor Everolimus (RAD001)
Biological Risk Factors for Stratification of HL Patients
The Role of the Microenvironment in HL
Analysing Differential Gene Expression and Genetic Lesions in HRS and L&H Cells to Identify New Therapeutic Targets
Latent EBV Infection of HRS Cells Predicts Adverse Outcome in Older Adult Classical HL Patients
A Taqman-Low Density Array to Predict Outcome in HL Using Paraffin Embedded Samples
Associations between Plasma Levels and Promoter Genotypes of IL-10 and IL-6 with Patient Characteristics and Outcome in HL
The Role of Innate Immunity in Cancer Progression
Glycosylated G-CSF Mobilises More Clonogenic Progentiors than Non-Glycosylated G-CSF
Treatment Associated Long Term Toxicity in HL Patients
Tuesday 06.11.2007
Scientific Session
Satellite Symposium
Main Program
Workshop
calendar export icon
Export calendar
Dose and Field Size: the EORTC Experience
Dose and Field Size: the GHSG Experience
Radioimmunotherapy (RIT) Applied to HL – a Useful Tool?
Yttrium-90 Radiolabeled Humanized Anti- CD25 Monoclonal Antibody, Daclizumab Provides Effective Therapy for Refractory and Relapsed HL
Involved Node Radiotherapy: Impact on Dose to PTV and Organs at Risk
Chemotherapy Alone versus Chemotherapy Plus Radiotherapy for Early Stage HL
Overview on Transplantation Strategies
Do we Need Allogeneic Transplantation in HL?
New Frontiers in Allogeneic Transplantation for HL
Reduced Intensity Allogeneic Stem Cell Transplantation (RIC-Allo) for Refractory / Relapsed HL. Preliminary Results of an EBMT Prospective Trial
Development of Gemcitabine in HL – US Perspective
Development of Gemcitabine in HL – European Perspective
New Perspectives in the Treatment of HL
PET-CT for Treatment Response Assessment in Lymphoma
PET for Early Response Adapted Therapy
Current Role and Future of PET in HL
FDG-PET for Assessment of Residual Tissue after Completion of Chemotherapy in HL – Report on the 2nd Interim Analysis of the PET Investigation in the Trial HD15 of the GHSG
Early Interim FDG-PET Overshadows the Prognostic Role of IPS in Advanced-stage HL Treated by Conventional ABVD Therapy
Interim Results of a UK NCRI Randomised Trial Comparing Involved Field Radiotherapy with No Further Treatment after 3 Cycles ABVD and a “Negative” PET Scan in Clinical Stages IA/IIA
North America: Cooperative Groups
Phase-II Study of Rituximab Plus ABVD for the Treatment of Newly Diagnosed Patients with Advanced Stage Classical HL
High-dose Therapy and ASCT versus Conventional Therapy for Patients with Advanced HL Responding to Front-line Therapy: Long Term Results
ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the Initial Treatment of Patients with Advanced HL. Preliminary Results of HD2000 GISL Trial
Speaker details
Ranjana
Advani
Speaker details
Berthe
Aleman
Speaker details
Richard
Ambinder
Speaker details
Ioannis
Anagnostopoulos
Speaker details
Paolo
Anderlini
Speaker details
Marc
André
Speaker details
Burton
Appel
Speaker details
James
Armitage
Speaker details
Cigdem
Atayar
Speaker details
Karl R. N.
Baumforth
Speaker details
Philip
Bierman
Speaker details
Magnus
Björkholm
Speaker details
Peter
Borchmann
Speaker details
Ramon
Bosch
Speaker details
Henning
Bredenfeld
Speaker details
Annegien
Broeks
Speaker details
George
Canellos
Speaker details
Patrice
Carde
Speaker details
Olivier
Casasnovas
Speaker details
Bruce
Cheson
Speaker details
Joseph
Connors
Speaker details
Lisa
Coussens
Speaker details
Volker
Diehl
Speaker details
Arjan
Diepstra
Speaker details
Bernd
Dörken
Speaker details
Gunilla
Enblad
Speaker details
Andreas
Engert
a.engert@uni-koeln.de
04.11.,
14:00–15:30,
Innovative Strategies in the Therapy of Hematological Malignancies
(Chair, Speaker)
04.11.,
16:00–17:30,
Treatment of Lymphomas: Current Strategies and Future Outlook
(Chair, Speaker)
06.11.,
17:30–18:45,
Closing Remarks
(Chair)
03.11.,
16:00–17:30,
Future Studies / Intergroup Trials
(Speaker)
05.11.,
10:30–12:00,
Early Stage HL
(Speaker)
Speaker details
Olav
Favier
Speaker details
Massimo
Federico
Speaker details
Richard
Fisher
Speaker details
Jonathan
Fromm
Speaker details
Andrea
Gallamini
Speaker details
Juan Fernando
Garcia Garcia
Speaker details
Randy
Gascoyne
Speaker details
Ulrich
Germing
Speaker details
Theodore
Girinsky
Speaker details
Christian
Gisselbrecht
Speaker details
Martin
Gramatzki
Speaker details
John
Gribben
Speaker details
Anton
Hagenbeek
Speaker details
Marjo
Hahka-Kemppinen
Speaker details
Michael
Hallek
Speaker details
Mads
Hansen
Speaker details
Martin-Leo
Hansmann
Speaker details
Frank
Hartmann
Speaker details
Michel
Henry-Amar
Speaker details
David
Hodgson
Speaker details
Stefan
Hohaus
Speaker details
Richard
Hoppe
Speaker details
Sandra
Horning
Speaker details
Eric
Hsi
Speaker details
Michael
Hummel
Speaker details
Martin
Hutchings
Speaker details
Tim
Illidge
Speaker details
Martin
Janz
Speaker details
Ruth
Jarrett
Speaker details
Peter
Johnson
Speaker details
Patrick
Johnston
Speaker details
Franziska
Jundt
Speaker details
Hans
Knecht
Speaker details
Guido
Kobbe
Speaker details
Carsten
Kobe
Speaker details
Dieter
Körholz
Speaker details
Martin
Kropff
Speaker details
Ralf
Küppers
Speaker details
Ola
Landgren
Speaker details
Judith
Landman-Parker
Speaker details
Ginna
Laport
Speaker details
Eli
Lilly
Speaker details
Yue
Ma
Speaker details
Stephen
Mackinnon
Speaker details
Massimo
Magagnoli
Speaker details
Stephan
Mathas
Speaker details
Matthew
Mealiffe
Speaker details
Angelo
Michele Carella
Speaker details
Rolf-Peter
Müller
Speaker details
Ralph
Naumann
Speaker details
Andrea
Ng
Speaker details
Alessandro
Noseda
Speaker details
Anders
Österborg
Speaker details
Michael
Pfreundschuh
Speaker details
Elke
Pogge von Strandmann
Speaker details
Aaron
Polliack
Speaker details
Sibrand
Poppema
Speaker details
Oliver
Press
Speaker details
John
Radford
Speaker details
John
Raemaekers
Speaker details
Aliyah
Rahemtullah
Speaker details
Daniel
Re
Speaker details
Fareed A.
Rehan
Speaker details
Bart
Reymen
Speaker details
Mathias
Rummel
Speaker details
Beatriz
Sanchez-Espiridion
Speaker details
Kerry J.
Savage
Speaker details
Uwe
Schlegel
Speaker details
Norbert
Schmitz
Speaker details
Cindy L.
Schwartz
Speaker details
Margaret
Shipp
Speaker details
Reiner
Siebert
Speaker details
Christian
Steidl
Speaker details
Harald
Stein
Speaker details
David
Straus
Speaker details
Sigrid
Stroobants
Speaker details
Anna
Sureda
Speaker details
Anthony
Swerdlow
Speaker details
Wayne
Tam
Speaker details
Jose
Thomas
Speaker details
Lorenz
Trümper
Speaker details
Anke
van den Berg
Speaker details
Flora
van Leeuwen
Speaker details
Andreas
von Deimling
Speaker details
Michael
von Wolf
Speaker details
Thomas
Waldmann
Speaker details
Richard
Ward
Speaker details
Mike
Watts
Speaker details
Clemens
Wendtner
Speaker details
Wolfgang
Wick
Speaker details
Joachim
Yahalom
Speaker details
Anas
Younes
younesa@mskcc.org
04.11.,
10:30–12:00,
Scientific Session on Translational Approaches
(Chair, Speaker)
06.11.,
12:15–13:45,
Role of Gemcitabine in the Treatment of Hodgkins Lymphoma
(Chair)
05.11.,
14:00–15:30,
Relapsed and Refractory Disease
(Speaker)
04.11.,
16:00–17:30,
Treatment of Lymphomas: Current Strategies and Future Outlook
(Speaker)
06.11.,
16:00–17:30,
Advanced Stages HL
(Speaker)
Basement
shift key
Hold SHIFT key while scrolling to zoom the map.
Hold ALT key while scrolling to rotate the map.
pinch-gesture
Use two fingers to zoom, move, or rotate the map.
Floor plan of Basement
Wardrobe
Stair to Ground Floor
Stair to Ground Floor
Weinkeller
Basement
First Floor
shift key
Hold SHIFT key while scrolling to zoom the map.
Hold ALT key while scrolling to rotate the map.
pinch-gesture
Use two fingers to zoom, move, or rotate the map.
Floor plan of First Floor
Stair to Ground Floor
Stair to Ground Floor
Großer Saal
Isabellensaal
First Floor
Dorint Hotel: Ground Level
shift key
Hold SHIFT key while scrolling to zoom the map.
Hold ALT key while scrolling to rotate the map.
pinch-gesture
Use two fingers to zoom, move, or rotate the map.
Floor plan of Dorint Hotel: Ground Level
Stair to Ground Floor
Stair to Ground Floor
Go to First Floor
Pipin II
Pipin I
Dorint Hotel: Ground Level
Dorint Hotel: First Floor
shift key
Hold SHIFT key while scrolling to zoom the map.
Hold ALT key while scrolling to rotate the map.
pinch-gesture
Use two fingers to zoom, move, or rotate the map.
Floor plan of Dorint Hotel: First Floor
Go to Ground Level
Martin
&
Augustin
Severin
Dorint Hotel: First Floor
Exhibition
shift key
Hold SHIFT key while scrolling to zoom the map.
Hold ALT key while scrolling to rotate the map.
pinch-gesture
Use two fingers to zoom, move, or rotate the map.
Map of the exhibition.
Map of the First Floor showing the location of 0 exhibitors.
Stair to Ground Floor
Stair to Ground Floor
Großer Saal
Isabellensaal